University of Lisbon at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Lisbon brings 3 presentations to ESGCT 2026 in Hamburg. Its work covers gene therapy for LAMA2-related muscular dystrophy, pairing a homology-directed repair strategy and AAV vectors with patient-derived three-dimensional models. A second strand uses RNA-based nanomedicines to shift immune responses against cancer.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Lisbon Lisbon, Portugal | |
Public university in Lisbon, Portugal. | Chair Wed Oct 28 8:30am–10:30am SESSION 3d: Non-viral vectors/nanotechnology and RNA therapeutics I Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies Poster Wed Oct 28 1:30pm–3:30pm A HDR strategy to treat LAMA2-MD in muscle cells Poster Wed Oct 28 1:30pm–3:30pm LAMA2-MD: testing rAAV-based gene therapy and developing 3D models using patient-derived cell lines Talk Fri Oct 30 11:30am–1:00pm Modulating Cancer Immunity with RNA-based Nano-Immunotherapies RNA and oligonucleotide therapiesCancer gene and cell therapy |
Instantly find 20 buyers from University of Lisbon
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction